A new vaccine against human papillomavirus (HPV), which can cause cervical cancer, could be even more effective, according to research published in the journal Cancer Epidemology, Biomarkers, and Prevention.
The new vaccine, developed by drug maker Merck, will protect against nine strains of HPV and could be 90 percent effective. The current vaccine, GARDASIL, protects against four strains and is 70 percent effective.
Vaccination against these additional five types of HPV could be good news for women worldwide, as certain strains of HPV are more common outside of the United States and Europe — HPV 52 and 58, for example, are more common in Asia.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The new vaccine is being reviewed by the FDA, and if it is approved, it could be available sometime in 2015, Time reports.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.